CDRH WOULD DESIGNATE STAFFER TO SPEED SUPPLEMENT REVIEWS UNDER KENNEDY AMENDMENT ADOPTED AT MARK-UP; THIRD-PARTY REVIEW LANGUAGE UNCHANGED
This article was originally published in The Gray Sheet
FDA's device, drug, biologics and veterinary medicine centers each would be required to designate a staffer responsible for expediting supplemental applications for approved products under an amendment by Sen. Edward Kennedy (D-Mass.) incorporated into the Senate FDA reform bill (S 830) during June 18 mark-up by the Senate Labor and Human Resources Committee.
You may also be interested in...
The US is to ship only half of doses for Pfizer, Moderna COVID-19 vaccines in the first instance, while Rhizen Pharmaceuticals starts a Phase I trial of a DHODH inhibitor.
Given its ever-growing role as a critical component of the global biopharma industry, you can’t afford not to be up to speed on Asia. This biweekly selection of insights from our experienced on-the-ground team will help.
Becton Dickinson will spend $1.2bn over the next four years to improve its drug-delivery device manufacturing capabilities. See what Eric Borin, president of BD, said about it here.